Pocket Program - CROI

CROI 2013 Session 8
i Monday, 8:30-9 am; Hall B1
Session 5–Plenary
HIV-1 Eradication Strategies: Design,
Assessment, and Clinical Consequences
16
Robert Siliciano
Johns Hopkins Univ Sch of Med, Baltimore, MD, US
Objectives: This session is directed to clinicians and scientists
interested in HIV-1 eradication studies. It is assumed participants
are familiar with fundamental aspects of HIV-1 treatment such as
the response to HAART, and the need for additional interventions
to eliminate the residual virus that persists despite HAART. At the
completion of the session, participants will be knowledgeable about
assays to measure viral reservoirs and the clinical consequences of
reductions in reservoir size induced by eradication strategies.
j Monday, 9-9:30 am; Hall B1
Session 6–Plenary
Reality Check: Is the End of AIDS in Sight?
17
Francois Dabis
Bordeaux Sch of Publ Hlth and INSERM U897, Univ Bordeaux,
Segalen, France
Objectives: This session is directed to clinicians and scientists
interested in the global perspective of the fight against HIV/AIDS.
It is assumed that participants are familiar with the concepts of
prevention and care and the programmatic differences between
resource-rich and -limited settings. At the completion of the session,
participants will be knowledgeable about the most recent advances
in biomedical prevention and the foreseeable scenarios for the
coming years.
k Monday, 10-11:30 am; B406
Session 7–Oral Abstracts
Neurocognitive Disorders: New Developments and
Therapies
Moderators:
Christina Marra, Univ of Washington Sch of Med, Seattle, US
Ann Ragin, Northwestern Univ Feinberg Sch of Med, Chicago, IL, US
10:00 18 Very Early Viral Infection of the Central
Nervous System without Evidence of
Compartmentalization during Acute HIV-1
Infection (RV254)
Serena Spudich* 1 , G Kijak 2,3 , J Ananworanich 4,5 , M Bose 2,3 ,
V Assawadarachai 5 , S Rattamanee 4,5 , E Sanders-Buell 2,3 , V Valcour 6 ,
J Kim 2 , S Tovanabutra 2,3 , and RV254/SEARCH 010 Study Group
1 Yale Univ, New Haven, CT, US;; 2 US Military HIV Res Prgm,
Walter Reed Army Inst of Res, Silver Spring, MD;; 3 Henry M Jackson
Fndn for the Advancement of Military Med, Bethesda, MD, US;;
4 SEARCH, The Thai Red Cross AIDS Res Ctr, HIVNAT, Bangkok;;
5 Armed Forces Res Inst for Med Sci, Bangkok, Thailand;; and 6 Univ
of California, San Francisco, US
10:15 19 Neuropsychological Performance in Acute HIV:
Determinants of Baseline Performance and
Effects of Immediate ART
Idil Kore* 1 , J Ananworanich 2,3,4 , V Valcour 5 , J Fletcher 2 ,
D Suttichom 2 , P Mangum 2 , L Jagodzinski 6 , J Kim 6 , S Spudich 1 ,
and RV254/SEARCH 010 Study Group
1 Yale Univ Sch of Med, New Haven, CT, US;; 2 SEARCH, The Thai
Red Cross AIDS Res Ctr, Bangkok;; 3 HIVNAT, Bangkok, Thailand;;
4 Faculty of Med, Chulalongkorn Univ, Bangkok, Thailand;; 5 Univ
of California, San Francisco, US;; and 6 US Military HIV Res Prgm,
Silver Spring, MD
10:30 20 A Randomized, Controlled Trial of a Central
Nervous System-targeted ART Strategy for
HIV-associated Neurocognitive Disorders
Ronald Ellis* 1 , F Vaida 1 , S Letendre 1 , R Haubrich 1 , R Heaton 1 ,
A McCutchan 1 , M Cherner 1 , A Umlauf 1 , N Sacktor 2 , and D Clifford 3
1 Univ of California, San Diego, US;; 2 Johns Hopkins Univ,
Baltimore, MD, US;; and 3 Washington Univ, St Louis, MO, US
10:45 21 Regional Brain Atrophy Is Associated with
Mitochondrial Dysfunction and Elevated
Mitochondrial Oxidative Stress in HIV + Individuals
K Kallianpur, M Gerschenson, T Umaki, D Chow, B Nakamoto,
D Libutti, M Lopez, J Taylor, L Marotz, and Cecilia Shikuma*
Univ of Hawaii, Honolulu, US
11:00 22 VLA-4 Treatment Blocks Virus Traffic to the
Gut and Brain Early, and Stabilizes CNS Injury
Late in Infection
Jennifer Campbell* 1 , P Autissier 1 , A MacLean 2 , T Burdo 1 ,
S Westmoreland 3 , G Gonzalez 4,5 , E-M Ratai 4,5 , and K Williams 1
1 Boston Coll, Chestnut Hill, MA, US;; 2 Tulane Natl Primate Res
Ctr, Covington, LA, US;; 3 New England Regional Primate Res Ctr,
Southborough, MA, US;; 4 Harvard Med Sch, Boston, MA, US;; and
5 Athinoula A Martinos Ctr for Biomed Imaging, Massachusetts Gen
Hosp, Boston, US
11:15 23 Central Nervous System Compartmentalization
of HIV-1 Subtype C Variants Early and Late in
Infection in Young Children
Christa Buckheit Sturdevant* 1 , A Dow 1 , C Jabara 1 , S Joseph 1 ,
G Schnell 2 , N Takamune 3 , M Mallewa 4 , R Heyderman 4 , A Van Rie 1 ,
and R Swanstrom 1
1 Univ of North Carolina at Chapel Hill, US;; 2 Univ of Washington,
Seattle, US;; 3 Kumamoto Univ, Japan;; and 4 Univ of Malawi Coll of
Med, Blantyre
k Monday, 10 am-12:15 pm; Ballroom 3-4
Session 8–Oral Abstracts
HIV Prevention: ARV, Counseling,
Contraception, and Condoms
Moderators:
Monica Gandhi, Univ of California, San Francisco, Sch of Med, US
James McIntyre, Anova Hlth Inst, Johannesburg, South Africa
10:00 24LB Long-acting Parenteral Formulation of
GSK1265744 Protects Macaques against
Repeated Intrarectal Challenges with SHIV
Chasity Andrews* 1 , A Gettie 1 , K Russell-Lodrigue 2 , L Moss 3 ,
H Mohri 1 , W Spreen 3 , C Cheng-Mayer 1 , Z Hong 3 , M Markowitz 1 ,
and D Ho 1
1 Aaron Diamond AIDS Res Ctr, The Rockefeller Univ, New York,
NY, US;; 2 Tulane Natl Primate Res Ctr, Covington, LA, US;; and
3 GlaxoSmithKline, Research Triangle Park, NC, US
10:15 25LB A Tenofovir Disoproxil Fumarate Intravaginal
Ring Completely Protects against Repeated
SHIV Vaginal Challenge in Nonhuman Primates
James Smith* 1 , R Rastogi 2 , R Teller 2 , P Srinivasan 1 , J Mitchell 1 ,
J McNicholl 1 , M Hendry 1 , P Mesquita 3 , P Kiser 2 , and B Herold 3
1 CDC, Atlanta, GA, US;; 2 Univ of Utah, Salt Lake City, US;; and
3 Albert Einstein Coll of Med, Bronx, NY, US
10:30 26LB Pre-exposure Prophylaxis for HIV in Women:
Daily Oral Tenofovir, Oral Tenofovir/
Emtricitabine, or Vaginal Tenofovir Gel
in the VOICE Study (MTN 003)
Jeanne Marrazzo* 1 , G Ramjee 2 , G Nair 3 , T Palanee 4 , B Mkhize 5 ,
C Nakabiito 6 , M Taljaard 7 , J Piper 8 , K Gomez Feliciano 9 ,
M Chirenje 10 , and VOICE Study Team
1 Univ of Washington, Seattle, US;; 2 HIV Prevention Res Unit,
Durban, South Africa;; 3 CAPRISA-eThekwini CRS, Duban, South
Africa;; 4 Witwatersrand Reproductive Hlth & HIV Inst;; 5 Perinatal
HIV Res Unit, Johannesburg, South Africa;; 6 Makerere-Johns
Hopkins Univ Res Collaboration, Kampala, Uganda;; 7 Aurum
Inst, Klerksdorp, South Africa;; 8 Division of AIDS, NIH, Bethesda,
MD, US;; 9 FHI360, Research Triangle Park, NC, US;; and 10 Univ of
Zimbabwe-UCSF CTU, Harare
10:45 27 No Excess in HIV Incidence after Stopping
Oral Emtricitabine/Tenofovir Pre-exposure
Prophylaxis: The iPrEx Trial
Robert Grant* 1,2 , J Guanira 3 , S Buchbinder 2,4 , C Mosquera 3 , V Veloso 5 ,
E Kallas 6 , M Mehrotra 1 , V McMahan 1 , R Amico 7 , D Glidden 2 , and iPrEx
Study Team
1 Gladstone Inst, San Francisco, CA, US;; 2 Univ of California, San
Francisco, US;; 3 INMENSA, Lima, Peru;; 4 San Francisco Dept of
Publ Hlth, CA, US;; 5 FIOCRUZ, Rio de Janeiro, Brazil;; 6 Univ of Sao
Paulo, Brazil;; and 7 Univ of Connecticut, Storrs, US
Program 3
Monday
March 4 Oral Sessions